INFLUENCE OF NEOADJUVANT INTRAARTERIAL INFUSION CHEMOTHERAPY ON APOPTOSIS AND MULTIDRUG RESISTANCE ASSOCIATED GENES OF ENDOMETRIAL CANCER

Many researches have proved that neoadjuvantintraarterial infusion chemotherapy (NIAC) is a useful method for the treatment of uterine cervical cancer[1, 2]while there are few reports about endometrial cancer[3Apoptosis has been shown to occur in various tumors in response to chemotherapeutic agents. It is not only related to the tumor response to chemotherapy, but also closely associated with the multidrug resistance[4, 5]. To date, no data have become available that shed light on the timin…     

SHORT－TIME ANALYSIS FOR ADJUVANT CHEMOTHERAPY IN PATIENTS WITH EARLY－STAGE BULKY CERVICAL CARCINOMA

Bulky early-stage cervical cancer is defined as stage I~IIa cervical carcinoma with the diameter of enlarged cervix reaching 4 centimeters or more. These patients have higher recurrence rate and poor prognosis compared to those with smaller tumors at the same stage[1-3]. In or study, 21 patients with early-stage bulky cervical cancer were assigned to receive the addition of cisplatin-based chemotherapy for 1~2 courses followed by radical hysterectomy and the effect was analyzed. MATERIS…     

CHEMOTHERAPY FOR ADVANCED NASOPHARYNGEAL CARCINOMA WITH METHOTREXATE, VINCRISTINE, CISPLATIN AND ADRIAMYCIN

Radiation therapy is the mainstay of treatment fornasopharyngeal carcinoma. With radiotherapy, the overall 5-year survival rate for stages I and II nasopharyngeal carcinoma is more than 80%. However, for the locally advanced (stages III and IV)cases, the 5-year survival rate is only 10%-40%. Death are due mainly to local-regional recurrence (about 47%) or distant metastasis （53%）[1-3]. Because the vast majority of nasopharyngeal carcinoma (>95%) is poorly differentiated squamous cell car…     

COMBINATION OF CHOLECYSTOJEJUNOSTOMY OR CHOLEDOCHJEJUNOSTOMY PERFUSION CHEMOTHERAPY AND RADIOTHERAPY FOR CANCER OF THE PANCRE

ＣＯＭＢＩＮＡＴＩＯＮＯＦＣＨＯＬＥＣＹＳＴＯＪＥＪＵＮＯＳＴＯＭＹＯＲＣＨＯＬＥＤＯＣＨＪＥＪＵＮＯＳＴＯＭＹＰＥＲＦＵＳＩＯＮＣＨＥＭＯＴＨＥＲＡＰＹＡＮＤＲＡＤＩＯＴＨＥＲＡＰＹＦＯＲＣＡＮＣＥＲＯＦＴＨＥＰＡＮＣＲＥＡＴＩＣＨＥＡＤＸｕｅＨｕ...     

ALTERNATING CHEMOTHERAPY AND FRACTIONATED RADIOTHERAPY AS A MODALITY FOR THE TREATMENT OF PRIMARY LIVER CANCER

ＡＬＴＥＲＮＡＴＩＮＧＣＨＥＭＯＴＨＥＲＡＰＹＡＮＤＦＲＡＣＴＩＯＮＡＴＥＤＲＡＤＩＯＴＨＥＲＡＰＹＡＳＡＭＯＤＡＬＩＴＹＦＯＲＴＨＥＴＲＥＡＴＭＥＮＴＯＦＰＲＩＭＡＲＹＬＩＶＥＲＣＡＮＣＥＲＬｕＪｉｚｈｅｎ陆继珍ＬｉＢｉｎｇｘｉｎ李炳鑫ＬｉｕＫａｎ...     

PROGNOSTIC FACTORS ANALYSIS FOR STAGEⅠ RECTAL CANCER

Colorectal cancer is one of the lethal malignancies severely threatening people抯 health in the world. Rectal cancer consists of 50-75% of colorectal cancer in China. Early detection of rectal cancer is rather difficult, leading to the rare detection of stage I rectal lesions. However, recent advances in colorectal cancer screening and early diagnosis have led to increasing number of stage I rectal cancer patients. Generally, the prognosis of stage I rectal cancer is rather good with 5 years…     

THE USE OF ANTI-HUMAN GLIOMA MONOCLONAL ANTIBODIES FOR TARGETING CHEMOTHERAPY OF BRAIN GLIOMAS(PREPARATION AND CYTOTOXIC PROPERTIES OF ANTIBODY-ADRIAMYCIN IMMUNOCONJUGATES)

Immunoconjugates are antibody-drug hybrid molecules which combine the exquisite selectivity or monoclonal antibodies with the potent toxicity of anticancer agents. A monoclonal antibody SZ39 against human brain gliomas was used as a drug carrier. Adriamycin (ADR) was bound covalently to SZ39 to form a SZ39-ADR conjugate. The cytotoxic activity of the SZ39-ADR conjugate was tested in vitro and demonstrated potent and specific killing of cells derived from a human malignant glioma. 50% inhibitory concentration (IC50) for SZ39-ADR to "target" cells was 8.14×10-9 M. An index of specificity between "target" and "non-target" cells was calculated to be 88-fold. These data suggest that the SZ39-ADR may use as a potent and cell type-specific agent and is a likely candidate for the targeting chemotherapy of malignant gliotnas.     

Ⅲ Ⅳa期鼻咽癌放疗前诱导化疗的前瞻性观察

目的:探讨用THP、DDP、5-FU方案在Ⅲ、Ⅳa期鼻咽癌放疗前诱导化疗1周期的疗效.方法:1996年12月～1998年6月收治了82例Ⅲ、Ⅳa期鼻咽部低分化鳞癌患者,按来院治疗时间分为A组(综合治疗组)42例和B组(单纯放疗组)40例.A组采用THP(吡柔比星)50mg/m2·d;DDP(顺铂)80mg/m2·d,和5-FU(5-氟脲嘧啶)200mg/m2·d,连续5天静脉点滴.诱导化疗结束后第3天开始放疗.结果:A组和B组患者鼻咽肿块控制率分别为88.0%、67.5%(P＜0.05);颈部肿块控制率分别为87.0%、42.9%(P＜0.01);A组和B组CR率分别为90.4%、52.5%(P＜0.01);5年生存率为50.0%、27.5%(P＜0.05).结论:THP、DDP、5-FU方案诱导化疗1周期能提高患者的局部控制率,改善近期疗效,同时提高患者的5年生存率.     

同期放化疗治疗Ⅲ～Ⅳa期鼻咽癌的前瞻性研究

目的 探讨同期放化疗能否提高Ⅲ～Ⅳa期鼻咽癌的疗效.方法 92例Ⅲ～Ⅳa期鼻咽癌患者随机分为两组.A组,单纯常规放疗组46例.B组,常规放疗 同期化疗46例.两组放疗方案相同均选用6 MV X线外照射或6～12 MeV电子线(用于颈部淋巴结转移灶的剂量补充照射)放射技术为面颈联合野DT 38Gy后,改耳前野避开脊髓加量及颈部切线野、上颈电子线外照射.原发灶和阳性淋巴结区DT 70～76 Gy/35～38次,7～8周,预防区DT50～60 Gy/25～30次,5～6周.化疗方案为DDP 40 mg静脉滴注,d1-3,平阳霉素16 mg静脉滴注,d1-3,每4周为1个疗程,共2个疗程,放射治疗开始于化疗结束后第2天进行.结果 3年无瘤生存率(DFS)A组47.8%(22/46)、B组71.7%(33/46),两者差异有统计学意义(χ2=5.47,P<0.05).3年总生存率(OS)A组58.7%(27/46),B组73.9%(34/46),两者差异无统计学意义(χ2=2.38,P＞0.05).结论 同期放化疗能提高中晚期鼻咽癌的无瘤生存率,对总生存率的提高也有一定的帮助.毒副反应虽有增加,但患者均能耐受.     

197例Ⅲ-Ⅳa期鼻咽癌患者的预后因素分析

目的:探讨Ⅲ-Ⅳa期鼻咽癌患者不同临床特征及不同治疗模式对鼻咽癌患者预后的影响.方法:对初治进行了根治性放疗的197例Ⅲ-Ⅳa期鼻咽癌患者的临床特征和治疗模式进行回顾性分析.结果:本组患者总的1、3、5年生存率分别为74%、51%、46%,中位生存时间50.6个月;单因素分析显示N分期对预后有显著性影响(P<0.05),多因素分析显示年龄、N分期是影响鼻咽癌生存的独立预后因素(P<0.05);同时接受化疗,联合放化疗组与单纯放疗组比较生存无显著性差异;联合放化疗组中,同期放化疗58例,同期放化疗组与单纯放疗组相比生存无显著性差异;同期放化疗组,基于DDP的同期放化疗34例,羟基喜树碱化疗24例,前者与单纯放疗组预后要好于后者,两两比较均有显著性差异,而前者与单纯放疗组相比,两组的生存无显著性差异.结论: 年龄越大,N分期越晚预后越差;放疗联合不规范的化疗未能改善局部晚期鼻咽癌的生存.     

Ⅲ期或Ⅳa1期肝癌肝移植的生活质量和生存率

目的 评价中期原发性肝癌(简称肝癌)肝移植的治疗效果,探讨更适合我国国情的肝癌肝移植标准.方法 以美国肝癌研究小组改良的TNM分期为基础,将肝癌分为早(Ⅰ期或Ⅱ期)、中(Ⅲ期或Ⅳa1期)、晚(Ⅳa2期或Ⅳb期)三期.用卡氏体能状况评分系统(Karnofsky performance status,KPS)作为生活质量评价工具,对我院2003年3月至2006年1月实施的中期肝癌肝移植分别于术前和术后评价其生活质量,记录术后无瘤存活时间和总存活时间,并计算不同时间点的无瘤生存率和总生存率.结果 中期肝癌患者术前生活质量属"低下"范畴,肝移植手术1周后生活质量逐步改善,3周时即显著优于术前(P=0.038),3个月和6个月时均有进一步改善.9个月时无瘤者生活质量即达到"良好"水平,与健康人相当,并在观察期结束时保持在这一高水平状态.术后1年、2年和3年生存率分别为91.0%、83.2%和80.0%,无瘤生存率分别为86.5%、81.9%和79.4%.结论 中期肝癌患者接受肝移植治疗能改善生活质量、延长生存时间,对中期肝癌可积极考虑肝移植治疗.     

术前化疗及手术治疗Ⅲ期,Ⅳa期恶性胸腺瘤

OBJECTIVE: To assess the effect of preoperative chemotherapy on invasive thymoma. METHODS: Fourteen patients with invasive thymoma (12 cases in Masaoka stage III and 2 cases in stage IV a) were treated with 3-4 cycles of CAVP (cyclophosphamide 600 mg/m2 D1, adriamycin 30 mg/m2 or epi-adriamycin 40 mg/m2 D1, vincristine 0.6 mg/m2 D1 or vindestine 3 mg/m2 D1, D8, cisplatin 30 mg/m2 D1, 2, 3). Following chemotherapy, patients were operated within 1-3 months. In 10 patients, sternotomy was performed and in 4 patients, anterolateral thoracotomy was performed. Radiotherapy was given with a total dose of 50-60 Gy in all patients except in those who were pathologically in complete remission. The patients were followed up for 6 months to 3 years. RESULTS: After chemotherapy, complete response was observed in 5 patients (35.7%) and partial response in 9 patients (64.3%). Nine patients received radical tumor resection and 5 patients received partial resection. Histologic/examination of the surgical specimens showed fibrosis of the remnant thymus in 5 patients. All but two patients survived in the follow-up period. Patient died from distant metastases at 18 and 24 months after treatment, respectively. CONCLUSION: Preoperative chemotherapy helps increase the resectability of stage III and IV a invasive thymoma. A longer follow-up period and more patients are needed to ascertain the impact of this treatment strategy on long-term survival.     

Ⅲ、Ⅳa期鼻咽癌同步放化疗联合辅助化疗的疗效观察

目的 探讨同步放化疗联合辅助化疗对Ⅲ、Ⅳa期鼻咽癌的疗效.方法 选取108例Ⅲ、Ⅳa期鼻咽癌,分为同步放化疗联合辅助化疗组54例(研究组)和单纯放疗组54例(对照组),两组放疗方法相同.研究组于放疗前给予DDP30mg/m2,d1～3;5-FU 750mg/m2,d1～3.化疗结束1～3d开始放疗.放疗第4周结束给予第2程化疗,放疗不间断,共2个疗程.辅助化疗于放疗结束后1～4w开始,3～4w重复1疗程,连用2个疗程.结果 研究组和对照组5年总生存率、无瘤生存率、远处转移率分别为63.0%和42.6%(P=0.034)、61.1%和3 8.9%(P=0.021)、18.5%和37.0%(P=0.032).在N3患者中,研究组和对照组的远处转移率分别为57.1%(4/7)和66.7%(4/6)(P=1.000).3级毒性反应主要表现为口咽黏膜炎,研究组和对照组分别为48.1%和27.8%(P=0.029).结论 同步放化疗联合辅助化疗可提高Ⅲ、Ⅳa期鼻咽癌的5年总生存率和无瘤生存率,减少远处转移率,但对N3患者远处转移率未显示优势.     

诱导化疗联合同期放化疗治疗Ⅲ、Ⅳa期鼻咽癌的临床研究

目的:评价单纯放疗和诱导化疗联合同期放化疗治疗Ⅲ、Ⅳa期鼻咽癌的毒副反应、临床疗效和对生存期的影响.方法:统计2000年至2005年我院诊治的Ⅲ、Ⅳa期鼻咽癌患者169例,其中113例患者接受单纯根治性放疗(对照组);56例患者接受长春瑞滨(NVB)联合顺铂(DDP)诱导化疗2周期后行根治性放疗,同期给予DDP每周方案化疗(研究组).两组患者进行临床疗效和毒副反应的比较,Kaplan-Meier法计算5年生存率和无瘤生存率.结果:研究组的鼻咽肿瘤和颈淋巴结完全消退率优于对照组(92.9％ vs80.5％,85.7％ vs 72.6％,P＜0.05).研究组和对照组的5年生存率和无瘤生存率分别为71.7％、61.3％和56.6％、47.6％,差异有统计学意义(P＜0.05).研究组毒副反应增加,以骨髓抑制、胃肠道反应和口腔黏膜炎为主.结论:诱导化疗联合同期放化疗可提高局部晚期鼻咽癌的临床疗效和生存率;毒副反应较大,但不影响治疗进程.     

同步放化疗Ⅲ-Ⅳa期鼻咽癌的临床观察(英文)

Objective:The aim of the study was to investigate the clinical effects of concurrent radiochemotherapy in treating locally advanced(Stages III-IVa)nasopharyngeal carcinomas(NPCs).Methods:A total of 95 patients who suffered from nasopharyngeal carcinoma(Stages III-IVa)was divided into two groups:Group concurrent radiochemotherapy(Group CCRT,n =49)and Group radiotherapy(Group RT,n=46).The two groups were both delivered conventional fractionated radiotherapy, while Group CCRT was delivered three cycles chemoth...     

Ⅲ、Ⅳa期鼻咽癌患者放疗同期化疗加辅助化疗的疗效

背景与目的:较多研究认为放疗前诱导化疗未能提高中晚期鼻咽癌的生存率,对放疗后的辅助化疗能否提高中晚期鼻咽癌的生存率有争议.有作者报道同期放化疗能提高中晚期鼻咽癌患者的疗效.本研究着重探讨放疗同期化疗加辅助化疗治疗Ⅲ、Ⅳa期鼻咽癌的疗效.方法:将80例Ⅲ、Ⅳa期鼻咽癌患者随机分为放疗同期化疗加辅助化疗组(研究组)及单纯放疗组(对照组),每组各40例.研究组于放疗第一周开始使用同期化疗,顺铂25 mg/m2静脉滴注,每周一次,连用6周.辅助化疗于放疗结束后一个月开始,顺铂25 mg/m2,静脉滴注,第1～3天;氟尿嘧啶1000 mg/m2,静脉滴注,第1～3天.每月一次,连用3次.放疗使用常规分割放疗,鼻咽部总剂量70Gy.对照组放疗方法与放疗加化疗组相同,不使用化疗.生存率采用Kaplan-Meier法,生存期的差别比较用log-rank检验,计数资料组间差异用卡方检验.结果:治疗后,研究组和对照组分别有34例和32例鼻咽肿瘤达到CR者(x2=0.35,P＞0.05);颈部淋巴结达到CR者分别为37例和30例(x2=4.50,P＜0.05).研究组1、3、5年生存率分别为92.7%、78.6%、64.2%,对照组1、3、5年生存率分别为81.2%、52.7%、42.3%,两组比较差异有显著性(P＜0.01).研究组1、3、5年无瘤生存率分别为91.2%、76.7%、63.5%,对照组1、3、5年无瘤生存率分别为78.2%、51.9%、40.3%,两组比较差异有显著性(P＜0.01).5年累积远处转移发生率研究组为15.0%,对照组为35.0%,两组比较差异有显著性(x2=4.27,P＜0.05).Ⅲ度口腔粘膜炎发生率研究组为75.0%,对照组为25.0%(x2=20.00,P＜0.01).结论:同期加辅助化疗联合放疗较单纯放疗提高了Ⅲ、Ⅳa期鼻咽癌的颈部淋巴结完全缓解率以及1、3、5年生存率和无瘤生存率,显著降低了远处转移的发生率,但增加了Ⅲ度口腔粘膜炎的发生率.     

后程加速分割放疗联合化疗治疗Ⅲ、Ⅳa期鼻咽癌的临床研究

目的：研究后程加速超分割放疗联合化疗治疗Ⅲ、Ⅳa期鼻咽癌的疗效。方法：将100例Ⅲ、Ⅳa期鼻咽癌随机分为后程加速超分割放疗联合化疗驵及常规分割放疗联合化疗组。后程加速超分割放疗联合化疗组于放疗前先行诱导化疗2次;化疗后先行常规分割放疗至鼻咽部剂量为40Gy,缩野后行后程加速超分割放疗至鼻咽部总剂量为70Gy;于放疗结束后再行辅助化疗2次。常规分割放疗联合化疗组化疗方法和后程加速分割放疗联合化疗组相同;放疗采用常规分割,鼻咽部总剂量为70Gy。结果：后程加速超分割放疗联合化疗组及常规分割放疗联合化疗组的2年实际生存率分别为83．6％及79．7％（P＞0．05）;2年无瘤生存率分别为76．5％及59．1％（P＜0．05）;2年局部区域无复发生存率分别为90．0％及69．7％（P＜0．05）。后程加速分割放疗联合化疗组有2例出现放射性后组脑神经损伤,常规分割放疗联合化疗组无严重后期并发症。结论：后程加速超分割放疗联合化疗较常规分割放疗联合化疗提高了Ⅲ、Ⅳa期鼻咽癌的2年局部区域无复发生存率2年无瘤生存率,但增加了后期产发症的发生率,其长期疗效及后期不良反应有待进一步随访观察。     

PLASMID pSK1002-MEDIATED MUTATOR EFFECT AND SOS RESPONSE AND ITS USE FOR DETECTION OF MUTAGENS

This work has studied plasmid pSK1002-mediated mutator effectand SOS response and its use for detection of mutagens.Thereults are as follows:The plasmid pSK1002(umcC'-'lacZ) couldenhance reverse mutagenesis induced by methyl methanesulfonate,4-nitro-quinoline-N-oxide in the strain TA1335/pSK1002.Maximum     

EXPERIMENT STUDY AND CLINICAL OBSERVATION WITH LIGATION METHOD FOR CLOSING BRONCHIAL STUMP FOLLOWING LOBECTOMY FOR LUNG NEOPLASMS

ＥＸＰＥＲＩＭＥＮＴＳＴＵＤＹＡＮＤＣＬＩＮＩＣＡＬＯＢＳＥＲＶＡＴＩＯＮＷＩＴＨＬＩＧＡＴＩＯＮＭＥＴＨＯＤＦＯＲＣＬＯＳＩＮＧＢＲＯＮＣＨＩＡＬＳＴＵＭＰＦＯＬＬＯＷＩＮＧＬＯＢＥＣＴＯＭＹＦＯＲＬＵＮＧＮＥＯＰＬＡＳＭＳＣｈｅｎＫｅｎｅｎｇ１陈...